Compare TPVG & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPVG | ALXO |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.6M | 172.8M |
| IPO Year | 2013 | 2020 |
| Metric | TPVG | ALXO |
|---|---|---|
| Price | $3.42 | $1.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $5.67 | $4.60 |
| AVG Volume (30 Days) | 259.3K | ★ 1.1M |
| Earning Date | 11-04-2026 | 11-16-2026 |
| Dividend Yield | ★ 25.91% | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ 0.59 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.69 | N/A |
| P/E Ratio | $6.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.51 | $0.86 |
| 52 Week High | $6.95 | $2.66 |
| Indicator | TPVG | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 21.34 | 44.18 |
| Support Level | N/A | $1.03 |
| Resistance Level | $5.56 | $1.34 |
| Average True Range (ATR) | 0.20 | 0.13 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 1.57 | 32.00 |
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the firm's operations are located across the United States.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.